Vitality Watch

Dossier pubmed preclinical 22-may-2026
Animal model, organoid, or cell-culture result — not yet human

circRNA-engineered macrophages mediate localized MMP9 neutralization to rejuvenate aged bone.

Key claim: Systemic aMMP9-LNPs reprogram macrophages into anti-MMP9 antibody biofactories, reducing stem-cell senescence and SASP and rejuvenating bone and cartilage in aged mice.

Abstract

Aging causes osteoporosis, delayed fracture repair, and osteoarthritis, but mechanisms and therapies remain unclear. Transcriptomics of serum and bone from older patients showed marked MMP9 upregulation, highlighting systemic MMP9 neutralization as a potential immunotherapy. Here, we developed ancircRNA-based antibody-engineering strategy that specifically targets macrophages, converting them into biofactories for anti-MMP9 antibodies. Central to this therapy is an apoptosis-mimicking lipid nanoparticle incorporating phosphatidylserine with an optimized formulation (aMMP9-LNP), which enhances macrophage-specific recognition and endocytosis. Leveraging inflammation-guided chemotaxis, this approach enables systemic, targeted MMP9 neutralization. In aged mice, systemic aMMP9-LNP reduced stem cell senescence, boosted osteogenesis, accelerated fracture repair, and mitigated cartilage degeneration. Mechanistically, MMP9 blockade dampened senescence-associated secretory phenotype, restored osteoblast-osteoclast balance, and lowered p21/MMP3. Biodistribution confirmed bone-targeted delivery with preserved tissue homeostasis, supporting translational potential. Collectively, our results identify MMP9 as a key effector and advance anmRNA immunotherapy for skeletal aging.

Why this matters

This finding introduces a modality — reprogramming resident macrophages into localized antibody biofactories via systemic circRNA-LNPs — that collapses the usual distance between a systemic drug and tissue-local SASP sources, with MMP9 as the first chosen target in aged bone. Mechanistically it ties the ECM-degrading-protease arm of skeletal aging to stem-cell senescence and inflammaging in a single intervention loop, and strategically it extends the targeted senotherapy menu beyond small-molecule senolytics, CAR-T, and nanoparticle delivery toward in situ biologic production. All effects are in aged mice; the biology-to-pitch gap for ‘macrophage biofactory immunotherapy’ remains the full preclinical-to-human translation step.

Source

Link

Briefing card

circRNA-engineered macrophages mediate localized MMP9 neutralization to rejuvenate aged bone.
Stage: preclinical · pubmed · 22-may-2026

Applies to researchers tracking macrophage-based biofactory immunotherapies — the MMP9-neutralization data remain mouse-only, with no human readout to act on.

Systemic aMMP9-LNPs reprogram macrophages into anti-MMP9 antibody biofactories, reducing stem-cell senescence and SASP and rejuvenating bone and cartilage in aged mice.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.bioactmat.2026.05.030

build build 880 · 2bcef25 · 2026-11-18